Clinicians' preferences for managing aneurysmal subarachnoid hemorrhage using endothelin receptor antagonists

BackgroundThe endothelin receptor antagonist (ERA) clazosentan is being investigated for the medical prevention of cerebral vasospasm and associated complications, such as delayed cerebral ischemia (DCI), after aneurysmal subarachnoid hemorrhage (aSAH). This study quantified how clinicians weigh the...

Full description

Bibliographic Details

Published in:	Frontiers in Neurology
Main Authors:	Sebastian Heidenreich, Myrto Trapali, Nicolas Krucien, Andrea Phillips-Beyer
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-03-01
Subjects:	discrete choice experiment (DCE) aneurysmal subarachnoid hemorrhage delayed cerebral ischemia endothelin receptor antagonist (ERA) physician preference clinician preference
Online Access:	https://www.frontiersin.org/articles/10.3389/fneur.2023.1102290/full